A study published May 22, 2026, in the journal Skin reveals that the drug secukinumab can resolve subclinical enthesitis—hidden inflammation where tendons and ligaments attach to bone—in patients with moderate-to-severe plaque psoriasis. Researchers at The Second Affiliated Hospital of Henan University of Science and Technology found that six weeks of treatment significantly reduced inflammatory edema in 76 patients who had not yet developed clinical psoriatic arthritis (PsA) symptoms.
How does secukinumab target hidden inflammation?
Secukinumab functions as an IL-17A inhibitor, a class of medication that blocks a specific protein involved in the immune response. According to the study, this blockade effectively resolves inflammatory edema before irreversible structural damage occurs. Ultrasound imaging performed during the trial showed significant thinning at multiple enthesial sites, with the most notable reduction occurring in the right Achilles tendon (P = 2.71×10-9).
Enthesitis is invisible to routine exams but detectable by ultrasound. The findings support using musculoskeletal ultrasound to screen at-risk psoriasis patients.
Why is early screening for psoriasis patients critical?
Detecting subclinical enthesitis allows clinicians to intervene before irreversible damage occurs. The research team suggests that using musculoskeletal ultrasound to screen at-risk psoriasis patients supports early intervention to potentially delay clinical PsA.
How do these findings compare to traditional treatment goals?
This study demonstrates that targeting the IL-17A pathway improves skin health. In the study group, participants saw significant improvements in all skin metrics—including PASI, DLQI, BSA, and IGA (all P < 0.001)—within the same six-week window that saw the reduction in tendon inflammation.
Frequently Asked Questions
What is subclinical enthesitis?
It is inflammation where tendons and ligaments attach to bone—that is present but not yet causing noticeable pain or physical symptoms.
Can this treatment prevent psoriatic arthritis?
The study suggests that early intervention with IL-17A inhibitors like secukinumab can resolve inflammatory edema, which may delay clinical PsA.
How is this condition diagnosed?
Routine physical exams often miss subclinical enthesitis. Musculoskeletal ultrasound is the diagnostic tool for detecting this early-stage inflammation.
Is this treatment suitable for all psoriasis patients?
The study specifically focused on 76 patients with moderate-to-severe plaque psoriasis. Patients should consult their healthcare provider to determine if IL-17A inhibitors are appropriate for their specific medical history.
Are you or a loved one managing psoriasis? Share your experiences with preventive monitoring in the comments below, or subscribe to our newsletter for the latest updates on rheumatology and dermatological research.
